isoniazid has been researched along with Co-infection in 84 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique." | 9.19 | Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014) |
| "Sixteen patients with TB-HIV co-infection received rifabutin 300 mg QD in combination with tuberculosis chemotherapy (initially pyrazinamide, isoniazid and ethambutol then only isoniazid), and were then randomized to receive isoniazid and LPV/r based ART with rifabutin 150 mg tiw or rifabutin 150 mg daily." | 9.19 | Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. ( Connolly, C; Harries, A; Kellerman, T; Lienhardt, C; McIlleron, H; Naiker, S; Pym, A; Reddy, T; Wiesner, L, 2014) |
| " The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 9.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
| "Isoniazid preventive therapy prevents active tuberculosis in people with HIV, but previous studies have found no evidence of benefit in people with HIV who had a negative tuberculin skin test, and a non-significant effect on mortality." | 9.12 | Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. ( Anglaret, X; Badje, A; Barnabas, RV; Boulle, A; Eholie, S; Ford, N; Gabillard, D; Golub, JE; Maartens, G; Rangaka, MX; Ross, JM; Shapiro, AE; Thomas, KK; Walker, AS; Wilkinson, RJ; Williams, BG, 2021) |
| "To systematically identify from qualitative data in the published literature the main barriers to adherence to isoniazid preventive therapy (IPT) for tuberculosis (TB) among people living with HIV/AIDS (PLWHA)." | 8.90 | Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data. ( Booth, A; Makanjuola, T; Taddese, HB, 2014) |
| "The World Health Organization (WHO) recommends active tuberculosis (TB) case finding among people living with human immunodeficiency virus (HIV) in resource-limited settings using a symptom-based algorithm; those without active TB disease should be offered isoniazid preventive therapy (IPT)." | 7.79 | Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia. ( Blumberg, HM; Kempker, R; Ofotokun, I; Stenehjem, E; Temesgen, O; Tenna, A; Zaeh, S, 2013) |
| " A novel dosing strategy that has the potential to reduce isoniazid-related toxicity and treatment failure is presented." | 5.56 | Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy. ( Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Janzén, D; Sundell, J, 2020) |
| "One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands." | 5.43 | HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. ( Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ, 2016) |
| "We identified significant gaps in the treatment for M." | 5.43 | Isoniazid therapy for Mycobacterium tuberculosis infection in HIV clinics, Los Angeles, California. ( Bolan, R; Chang, AH; Dubé, MP; Ghosh, JK; Kerndt, PR; Shin, SS; Yang, OO, 2016) |
| "This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique." | 5.19 | Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014) |
| "Sixteen patients with TB-HIV co-infection received rifabutin 300 mg QD in combination with tuberculosis chemotherapy (initially pyrazinamide, isoniazid and ethambutol then only isoniazid), and were then randomized to receive isoniazid and LPV/r based ART with rifabutin 150 mg tiw or rifabutin 150 mg daily." | 5.19 | Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. ( Connolly, C; Harries, A; Kellerman, T; Lienhardt, C; McIlleron, H; Naiker, S; Pym, A; Reddy, T; Wiesner, L, 2014) |
| " The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 5.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
| "Isoniazid preventive therapy prevents active tuberculosis in people with HIV, but previous studies have found no evidence of benefit in people with HIV who had a negative tuberculin skin test, and a non-significant effect on mortality." | 5.12 | Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. ( Anglaret, X; Badje, A; Barnabas, RV; Boulle, A; Eholie, S; Ford, N; Gabillard, D; Golub, JE; Maartens, G; Rangaka, MX; Ross, JM; Shapiro, AE; Thomas, KK; Walker, AS; Wilkinson, RJ; Williams, BG, 2021) |
| "Efavirenz (EFV) and rifampicin-isoniazid (RH) are cornerstone drugs in human immunodeficiency virus (HIV)-tuberculosis (TB) coinfection treatment but with complex drug interactions, efficacy and safety challenges." | 4.98 | Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review. ( Atwine, D; Bonnet, M; Taburet, AM, 2018) |
| "To systematically identify from qualitative data in the published literature the main barriers to adherence to isoniazid preventive therapy (IPT) for tuberculosis (TB) among people living with HIV/AIDS (PLWHA)." | 4.90 | Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data. ( Booth, A; Makanjuola, T; Taddese, HB, 2014) |
| "Because treatment can only be initiated when infection is detected, and is guided by the results of antimicrobial susceptibility testing, there recently has been a marked increase in the development and testing of novel assays designed to detect Mycobacterium tuberculosis complex, with or without simultaneous detection of resistance to isoniazid and/or rifampin." | 4.89 | Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing. ( Wilson, ML, 2013) |
| " The secondary objective was to determine the overall incidence of hepatitis in children on Anti tubercular treatment (ATT) and isoniazid prophylactic therapy (IPT)." | 3.91 | Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children. ( Indumathi, CK; Jain, S; Krishnamurthy, S; Sethuraman, A, 2019) |
| "The prevalence of tuberculosis among HIV positive patients in Xinjiang was higher than in China taken as a whole, and HIV was diagnosed late, with underuse of isoniazid preventive therapy." | 3.85 | High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China. ( Andersson, R; Maimaiti, R; Mijiti, P; Musa, M; Pan, K; Wubili, M; Zhang, Y, 2017) |
| "The World Health Organization recommends for tuberculosis retreatment a regimen of isoniazid (H), rifampicin (R), ethambutol (E), pyrazinamide (Z), and streptomycin (S) for 2 months, followed by H, R, E, and Z for 1 month and H, R, and E for 5 months." | 3.81 | High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study. ( Acuña-Villaorduña, C; Ayakaka, I; Dryden-Peterson, S; Fennelly, KP; Hosford, J; Jones-López, EC; Nakubulwa, S; Okwera, A; Reilly, N; Worodria, W, 2015) |
| "Isoniazid preventive therapy (IPT) with antiretroviral therapy (ART) reduces incident tuberculosis among patients infected with the human immunodeficiency virus." | 3.80 | Isoniazid preventive therapy use among patients on antiretroviral therapy: a missed opportunity. ( Charalambous, S; Chihota, VN; Churchyard, GJ; Kufa, T, 2014) |
| " TB-exposed newborns requiring isoniazid preventive therapy (IPT) or anti-tuberculosis treatment were followed to 6 months of age." | 3.80 | Determinants of tuberculosis treatment completion among newborns in a high-burden setting. ( Bekker, A; Du Preez, K; Hesseling, AC; Schaaf, HS; Slogrove, AL, 2014) |
| "The World Health Organization (WHO) recommends active tuberculosis (TB) case finding among people living with human immunodeficiency virus (HIV) in resource-limited settings using a symptom-based algorithm; those without active TB disease should be offered isoniazid preventive therapy (IPT)." | 3.79 | Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia. ( Blumberg, HM; Kempker, R; Ofotokun, I; Stenehjem, E; Temesgen, O; Tenna, A; Zaeh, S, 2013) |
| "We enrolled HIV-infected Ugandans with pulmonary tuberculosis." | 2.87 | Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. ( Buzibye, A; Byakika-Kibwika, P; Castelnuovo, B; Corti, N; de Kock, M; Denti, P; Eberhard, N; Fehr, JS; Gutteck, U; Henning, L; Jetter, A; Joloba, M; Kambugu, A; Kamya, MR; Lamorde, M; Ledergerber, B; Manabe, YC; Matovu, J; Muller, D; Musaazi, J; Sekaggya-Wiltshire, C; von Braun, A, 2018) |
| " Nonlinear mixed-effects modeling found that influential covariates for the pharmacokinetics were weight, sex, and a 30% increased bioavailability among heterozygous carriers of SLCO1B1 rs1104581 (previously associated with low rifampin concentrations)." | 2.82 | Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. ( Egan, D; Hennig, S; Kellerman, T; McIlleron, H; Naiker, S; Owen, A; Pym, A; Reddy, T; Wiesner, L, 2016) |
| "There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (<12 months of age), when drug disposition may differ." | 2.82 | Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ( Bekker, A; Donald, PR; Draper, HR; Hesseling, AC; McIlleron, HM; Murray, S; Schaaf, HS; van der Laan, L; Wiesner, L, 2016) |
| "HIV is the top and tuberculosis is the second leading cause of death from infectious disease worldwide, with an estimated 8." | 2.50 | Tuberculosis and HIV co-infection in children. ( Chiappini, E; de Martino, M; Galli, L; Thorne, C; Turkova, A; Venturini, E, 2014) |
| "Drug-resistant tuberculous meningitis is associated with a high mortality." | 2.49 | Drug-resistant tuberculous meningitis. ( Agrawal, A; Garg, R; Garg, RK; Jain, A; Malhotra, HS, 2013) |
| " A novel dosing strategy that has the potential to reduce isoniazid-related toxicity and treatment failure is presented." | 1.56 | Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy. ( Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Janzén, D; Sundell, J, 2020) |
| " Isoniazid, rifampin, and pyrazinamide concentration-time profiles and treatment outcome were obtained from 161 Indian children with drug-sensitive tuberculosis undergoing thrice-weekly dosing as per previous Indian pediatric guidelines." | 1.48 | Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications. ( Bhavani, PK; Dooley, KE; Gangadevi, NP; Guiastrennec, B; Gupta, A; Karlsson, MO; Kumar, AKH; Ramachandran, G; Savic, RM; Swaminathan, S, 2018) |
| "If isoniazid Cmax was <4." | 1.46 | Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. ( Denti, P; Gumbo, T; Lesosky, M; McIlleron, H; Meintjes, G; Pasipanodya, JG; Rockwood, N; Sirgel, F; Wilkinson, RJ, 2017) |
| " The aim of this analysis was to characterize factors contributing to the variability in exposure and to evaluate drug exposures using alternative doses, thus providing evidence to support revised dosing recommendations for drug-susceptible and multidrug-resistant tuberculosis (MDR-TB)." | 1.46 | Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. ( Chirehwa, MT; Denti, P; McIlleron, H; Mthiyane, T; Onyebujoh, P; Rustomjee, R; Smith, P, 2017) |
| "Rifampin is a key sterilizing drug in the treatment of tuberculosis (TB)." | 1.43 | Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction. ( Chirehwa, MT; Denti, P; McIlleron, H; Mthiyane, T; Onyebujoh, P; Rustomjee, R; Smith, P, 2016) |
| "HIV-infected adults with substance abuse (tobacco smoking, khat chewing and alcohol) should be prioritised for TB screening." | 1.43 | Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case-control study. ( Alemu, YM; Awoke, W; Wilder-Smith, A, 2016) |
| "We identified significant gaps in the treatment for M." | 1.43 | Isoniazid therapy for Mycobacterium tuberculosis infection in HIV clinics, Los Angeles, California. ( Bolan, R; Chang, AH; Dubé, MP; Ghosh, JK; Kerndt, PR; Shin, SS; Yang, OO, 2016) |
| "One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands." | 1.43 | HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. ( Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ, 2016) |
| "tuberculosis strain in a patient with mixed infection." | 1.39 | Undetected multidrug-resistant tuberculosis amplified by first-line therapy in mixed infection. ( Bremang, S; Casey, R; Connell, D; Evans, JT; Hawkey, PM; Hingley-Wilson, SM; Jepson, A; Kon, OM; Lalvani, A; Philip, S; Smith, GE, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 77 (91.67) | 24.3611 |
| 2020's | 7 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Yanes-Lane, M | 1 |
| Ortiz-Brizuela, E | 1 |
| Campbell, JR | 1 |
| Benedetti, A | 1 |
| Churchyard, G | 1 |
| Oxlade, O | 1 |
| Menzies, D | 2 |
| Yang, H | 1 |
| Antwi, S | 1 |
| Maranchick, N | 1 |
| Dompreh, A | 1 |
| Amissah, AK | 1 |
| Sly-Moore, E | 1 |
| Martyn-Dickens, C | 1 |
| Opoku, T | 1 |
| Enimil, A | 1 |
| Bosomtwe, D | 1 |
| Ojewale, O | 1 |
| Sarfo, AD | 1 |
| Appiah, AF | 1 |
| Kusi-Amponsah, I | 1 |
| Dong, SK | 1 |
| Osei Kuffour, B | 1 |
| Morgan, R | 1 |
| Alshaer, MH | 1 |
| Peloquin, CA | 1 |
| Kwara, A | 1 |
| Baraki, AG | 1 |
| Gezie, LD | 1 |
| Zeleke, EG | 1 |
| Awoke, T | 1 |
| Tsegaye, AT | 1 |
| Sundell, J | 1 |
| Bienvenu, E | 1 |
| Janzén, D | 1 |
| Birgersson, S | 1 |
| Äbelö, A | 1 |
| Ashton, M | 1 |
| Alemu, A | 1 |
| Yesuf, A | 1 |
| Zerihun, B | 1 |
| Getu, M | 1 |
| Worku, T | 1 |
| Bitew, ZW | 1 |
| Roscoe, C | 1 |
| Lockhart, C | 1 |
| de Klerk, M | 1 |
| Baughman, A | 1 |
| Agolory, S | 1 |
| Gawanab, M | 1 |
| Menzies, H | 1 |
| Jonas, A | 1 |
| Salomo, N | 1 |
| Taffa, N | 1 |
| Lowrance, D | 1 |
| Robsky, K | 1 |
| Tollefson, D | 1 |
| Pevzner, E | 1 |
| Hamunime, N | 1 |
| Mavhunga, F | 1 |
| Mungunda, H | 1 |
| Ross, JM | 1 |
| Badje, A | 1 |
| Rangaka, MX | 2 |
| Walker, AS | 1 |
| Shapiro, AE | 1 |
| Thomas, KK | 1 |
| Anglaret, X | 1 |
| Eholie, S | 1 |
| Gabillard, D | 1 |
| Boulle, A | 3 |
| Maartens, G | 1 |
| Wilkinson, RJ | 4 |
| Ford, N | 2 |
| Golub, JE | 2 |
| Williams, BG | 1 |
| Barnabas, RV | 1 |
| Hoffmann, J | 1 |
| Chedid, C | 1 |
| Ocheretina, O | 2 |
| Masetti, C | 1 |
| Joseph, P | 1 |
| Mabou, MM | 2 |
| Mathon, JE | 1 |
| Francois, EM | 1 |
| Gebelin, J | 1 |
| Babin, FX | 1 |
| Raskine, L | 1 |
| Pape, JW | 3 |
| Chirehwa, MT | 2 |
| McIlleron, H | 8 |
| Rustomjee, R | 3 |
| Mthiyane, T | 2 |
| Onyebujoh, P | 2 |
| Smith, P | 4 |
| Denti, P | 5 |
| Baghaei, P | 1 |
| Tabarsi, P | 1 |
| Moniri, A | 1 |
| Marjani, M | 1 |
| Farnia, P | 1 |
| Jabbehdari, S | 1 |
| Velayati, AA | 1 |
| Sekaggya-Wiltshire, C | 3 |
| Castelnuovo, B | 3 |
| von Braun, A | 3 |
| Musaazi, J | 2 |
| Muller, D | 3 |
| Buzibye, A | 3 |
| Gutteck, U | 3 |
| Henning, L | 2 |
| Ledergerber, B | 3 |
| Corti, N | 3 |
| Lamorde, M | 3 |
| Fehr, J | 2 |
| Kambugu, A | 3 |
| Wondale, B | 1 |
| Medihn, G | 1 |
| Teklu, T | 1 |
| Mersha, W | 1 |
| Tamirat, M | 1 |
| Ameni, G | 1 |
| Guiastrennec, B | 1 |
| Ramachandran, G | 1 |
| Karlsson, MO | 1 |
| Kumar, AKH | 1 |
| Bhavani, PK | 1 |
| Gangadevi, NP | 1 |
| Swaminathan, S | 1 |
| Gupta, A | 1 |
| Dooley, KE | 1 |
| Savic, RM | 1 |
| Adane, K | 1 |
| Spigt, M | 1 |
| Dinant, GJ | 1 |
| de Kock, M | 1 |
| Jetter, A | 1 |
| Byakika-Kibwika, P | 2 |
| Eberhard, N | 1 |
| Matovu, J | 1 |
| Joloba, M | 1 |
| Manabe, YC | 2 |
| Kamya, MR | 2 |
| Fehr, JS | 1 |
| Pasipanodya, JG | 2 |
| Gumbo, T | 2 |
| Atwine, D | 1 |
| Bonnet, M | 2 |
| Taburet, AM | 2 |
| du Preez, K | 3 |
| du Plessis, L | 1 |
| O'Connell, N | 1 |
| Hesseling, AC | 7 |
| Zhao, Y | 1 |
| Fox, T | 1 |
| Manning, K | 1 |
| Stewart, A | 1 |
| Tiffin, N | 1 |
| Khomo, N | 1 |
| Leslie, J | 1 |
| Mudaly, V | 1 |
| Kock, Y | 1 |
| Meintjes, G | 3 |
| Wasserman, S | 1 |
| Alffenaar, JC | 1 |
| Heysell, SK | 1 |
| Mpagama, SG | 1 |
| Obregón, G | 1 |
| Zevallos, K | 1 |
| Alarcón, V | 1 |
| Puyén, ZM | 1 |
| Chávez Inagaki, O | 1 |
| Mendoza-Ticona, A | 1 |
| Alarcón-Arrascue, E | 1 |
| Heldal, E | 1 |
| Moore, DAJ | 1 |
| Indumathi, CK | 1 |
| Sethuraman, A | 1 |
| Jain, S | 1 |
| Krishnamurthy, S | 1 |
| Walsh, KF | 1 |
| Souroutzidis, A | 1 |
| Vilbrun, SC | 1 |
| Peeples, M | 1 |
| Joissaint, G | 1 |
| Delva, S | 1 |
| Widmann, P | 1 |
| Royal, G | 1 |
| Pry, J | 1 |
| Bang, H | 1 |
| Koenig, SP | 1 |
| Sabasaba, A | 1 |
| Mwambi, H | 1 |
| Somi, G | 1 |
| Ramadhani, A | 2 |
| Mahande, MJ | 1 |
| Gezae, KE | 1 |
| Abebe, HT | 1 |
| Gebretsadik, LG | 1 |
| Beshir, MT | 1 |
| Beyene, AH | 1 |
| Tlaye, KG | 1 |
| Demelew, TM | 1 |
| Wilson, ML | 1 |
| Morano, JP | 1 |
| Walton, MR | 1 |
| Zelenev, A | 1 |
| Bruce, RD | 1 |
| Altice, FL | 1 |
| Garg, RK | 1 |
| Jain, A | 1 |
| Malhotra, HS | 1 |
| Agrawal, A | 1 |
| Garg, R | 1 |
| Hingley-Wilson, SM | 1 |
| Casey, R | 1 |
| Connell, D | 1 |
| Bremang, S | 1 |
| Evans, JT | 1 |
| Hawkey, PM | 1 |
| Smith, GE | 1 |
| Jepson, A | 1 |
| Philip, S | 1 |
| Kon, OM | 1 |
| Lalvani, A | 1 |
| Smythe, W | 1 |
| Merle, CS | 1 |
| Gninafon, M | 1 |
| Lo, MB | 1 |
| Bah-Sow, O | 1 |
| Olliaro, PL | 1 |
| Lienhardt, C | 4 |
| Horton, J | 1 |
| Simonsson, US | 1 |
| Wejse, C | 1 |
| Furtado, A | 1 |
| Camara, C | 1 |
| Lüneborg-Nielsen, M | 1 |
| Sodemann, M | 1 |
| Gerstoft, J | 1 |
| Katzenstein, TL | 1 |
| Zaeh, S | 1 |
| Kempker, R | 1 |
| Stenehjem, E | 1 |
| Blumberg, HM | 1 |
| Temesgen, O | 1 |
| Ofotokun, I | 1 |
| Tenna, A | 1 |
| Makanjuola, T | 1 |
| Taddese, HB | 1 |
| Booth, A | 1 |
| Kurup, R | 1 |
| George, C | 1 |
| Venturini, E | 1 |
| Turkova, A | 1 |
| Chiappini, E | 1 |
| Galli, L | 1 |
| de Martino, M | 1 |
| Thorne, C | 1 |
| Bhatt, NB | 1 |
| Barau, C | 1 |
| Amin, A | 1 |
| Baudin, E | 1 |
| Meggi, B | 1 |
| Silva, C | 1 |
| Furlan, V | 1 |
| Grinsztejn, B | 1 |
| Barrail-Tran, A | 1 |
| Kufa, T | 1 |
| Chihota, VN | 1 |
| Charalambous, S | 2 |
| Churchyard, GJ | 2 |
| Gray, DM | 1 |
| Workman, LJ | 1 |
| Lombard, CJ | 1 |
| Jennings, T | 1 |
| Innes, S | 1 |
| Grobbelaar, CJ | 1 |
| Cotton, MF | 2 |
| Zar, HJ | 2 |
| Bekker, A | 2 |
| Slogrove, AL | 1 |
| Schaaf, HS | 5 |
| Amlabu, V | 1 |
| Mulligan, C | 1 |
| Jele, N | 1 |
| Evans, A | 1 |
| Gray, D | 1 |
| Jindani, A | 1 |
| Harrison, TS | 1 |
| Nunn, AJ | 1 |
| Phillips, PP | 1 |
| Hatherill, M | 1 |
| Geldenhuys, H | 1 |
| McIlleron, HM | 2 |
| Zvada, SP | 1 |
| Mungofa, S | 1 |
| Shah, NA | 1 |
| Zizhou, S | 1 |
| Magweta, L | 1 |
| Shepherd, J | 1 |
| Nyirenda, S | 1 |
| van Dijk, JH | 1 |
| Clouting, HE | 1 |
| Coleman, D | 1 |
| Bateson, AL | 1 |
| McHugh, TD | 2 |
| Butcher, PD | 1 |
| Mitchison, DA | 1 |
| Oshi, SN | 1 |
| Alobu, I | 1 |
| Ukwaja, KN | 1 |
| Oshi, DC | 1 |
| Naiker, S | 2 |
| Connolly, C | 1 |
| Wiesner, L | 4 |
| Kellerman, T | 2 |
| Reddy, T | 2 |
| Harries, A | 1 |
| Pym, A | 3 |
| Martinez-Longoria, CA | 1 |
| Rubio-Perez, NE | 1 |
| Rios-Solis, JE | 1 |
| Garcia-Rodriguez, F | 1 |
| Stout, JE | 1 |
| Andrews, JR | 1 |
| Azadi, M | 1 |
| Bishai, DM | 1 |
| Dowdy, DW | 1 |
| Moulton, LH | 1 |
| Cavalcante, S | 2 |
| Saraceni, V | 1 |
| Pacheco, AG | 1 |
| Cohn, S | 1 |
| Chaisson, RE | 1 |
| Durovni, B | 1 |
| Honeyborne, I | 1 |
| Lipman, MC | 1 |
| Eckold, C | 1 |
| Evangelopoulos, D | 1 |
| Gillespie, SH | 1 |
| Green, EP | 1 |
| Catalani, C | 1 |
| Diero, L | 1 |
| Carter, EJ | 1 |
| Gardner, A | 1 |
| Ndwiga, C | 1 |
| Keny, A | 1 |
| Owiti, P | 1 |
| Israelski, D | 1 |
| Biondich, P | 1 |
| Seung, KJ | 1 |
| Keshavjee, S | 1 |
| Rich, ML | 1 |
| Acuña-Villaorduña, C | 1 |
| Ayakaka, I | 1 |
| Dryden-Peterson, S | 1 |
| Nakubulwa, S | 1 |
| Worodria, W | 1 |
| Reilly, N | 1 |
| Hosford, J | 1 |
| Fennelly, KP | 1 |
| Okwera, A | 1 |
| Jones-López, EC | 1 |
| Shen, L | 1 |
| Escuyer, VE | 1 |
| Royal-Mardi, G | 1 |
| Collins, SE | 1 |
| Fitzgerald, DW | 1 |
| Getahun, H | 1 |
| Matteelli, A | 1 |
| Abubakar, I | 1 |
| Aziz, MA | 1 |
| Baddeley, A | 1 |
| Barreira, D | 1 |
| Den Boon, S | 1 |
| Borroto Gutierrez, SM | 1 |
| Bruchfeld, J | 1 |
| Burhan, E | 1 |
| Cedillos, R | 1 |
| Chaisson, R | 1 |
| Chee, CB | 1 |
| Chesire, L | 1 |
| Corbett, E | 1 |
| Dara, M | 1 |
| Denholm, J | 1 |
| de Vries, G | 1 |
| Falzon, D | 1 |
| Gale-Rowe, M | 1 |
| Gilpin, C | 1 |
| Girardi, E | 1 |
| Go, UY | 1 |
| Govindasamy, D | 1 |
| D Grant, A | 1 |
| Grzemska, M | 1 |
| Harris, R | 1 |
| Horsburgh, CR | 2 |
| Ismayilov, A | 1 |
| Jaramillo, E | 1 |
| Kik, S | 1 |
| Kranzer, K | 1 |
| LoBue, P | 1 |
| Lönnroth, K | 1 |
| Marks, G | 1 |
| Migliori, GB | 1 |
| Mosca, D | 1 |
| Mukadi, YD | 1 |
| Mwinga, A | 1 |
| Nelson, L | 1 |
| Nishikiori, N | 1 |
| Oordt-Speets, A | 1 |
| Reis, A | 1 |
| Rotz, L | 1 |
| Sandgren, A | 1 |
| Sañé Schepisi, M | 1 |
| Schünemann, HJ | 1 |
| Sharma, SK | 1 |
| Sotgiu, G | 1 |
| Stagg, HR | 1 |
| Sterling, TR | 1 |
| Tayeb, T | 1 |
| Uplekar, M | 1 |
| van der Werf, MJ | 1 |
| Vandevelde, W | 1 |
| van Kessel, F | 1 |
| van't Hoog, A | 1 |
| Varma, JK | 1 |
| Vezhnina, N | 1 |
| Voniatis, C | 1 |
| Vonk Noordegraaf-Schouten, M | 1 |
| Weil, D | 1 |
| Weyer, K | 1 |
| Yoshiyama, T | 1 |
| Zellweger, JP | 1 |
| Raviglione, M | 1 |
| van der Watt, JJ | 1 |
| Benatar, MG | 1 |
| Harrison, TB | 1 |
| Carrara, H | 1 |
| Heckmann, JM | 1 |
| Hennig, S | 1 |
| Egan, D | 1 |
| Owen, A | 1 |
| Harries, AD | 1 |
| Lawn, SD | 1 |
| Suthar, AB | 1 |
| Granich, R | 1 |
| Barnett, B | 1 |
| Gokhale, RH | 1 |
| Krysiak, R | 1 |
| Kanyemba, C | 1 |
| Chikaonda, T | 1 |
| Bokosi, M | 1 |
| Mukuzunga, C | 1 |
| Saidi, F | 1 |
| Phiri, S | 2 |
| Hoffman, IF | 1 |
| Hosseinipour, MC | 1 |
| Draper, HR | 1 |
| van der Laan, L | 1 |
| Murray, S | 1 |
| Donald, PR | 2 |
| Alemu, YM | 1 |
| Awoke, W | 1 |
| Wilder-Smith, A | 1 |
| Mukherjee, A | 1 |
| Velpandian, T | 1 |
| Singla, M | 1 |
| Kanhiya, K | 1 |
| Kabra, SK | 1 |
| Lodha, R | 1 |
| Shin, SS | 1 |
| Chang, AH | 1 |
| Ghosh, JK | 1 |
| Dubé, MP | 1 |
| Bolan, R | 1 |
| Yang, OO | 1 |
| Kerndt, PR | 1 |
| Bélard, S | 1 |
| Remppis, J | 1 |
| Bootsma, S | 1 |
| Janssen, S | 1 |
| Kombila, DU | 1 |
| Beyeme, JO | 1 |
| Rossatanga, EG | 1 |
| Kokou, C | 1 |
| Osbak, KK | 1 |
| Obiang Mba, RM | 1 |
| Kaba, HM | 1 |
| Traoré, AN | 1 |
| Ehrhardt, J | 1 |
| Bache, EB | 1 |
| Flamen, A | 1 |
| Rüsch-Gerdes, S | 1 |
| Frank, M | 1 |
| Adegnika, AA | 1 |
| Lell, B | 1 |
| Niemann, S | 1 |
| Kremsner, PG | 1 |
| Loembé, MM | 1 |
| Alabi, AS | 1 |
| Grobusch, MP | 1 |
| Maritz, ER | 1 |
| Montepiedra, G | 1 |
| Liu, L | 1 |
| Mitchell, CD | 1 |
| Madhi, SA | 1 |
| Bobat, R | 1 |
| Violari, A | 1 |
| Ogwu, A | 1 |
| Rockwood, N | 2 |
| Chirehwa, M | 1 |
| Garcia-Prats, AJ | 1 |
| Rautenbach, C | 1 |
| Okoli, EI | 1 |
| Roets, L | 1 |
| John, SF | 1 |
| Aniemeke, E | 1 |
| Ha, NP | 1 |
| Chong, CR | 1 |
| Gu, P | 1 |
| Zhou, J | 1 |
| Zhang, Y | 2 |
| Graviss, EA | 1 |
| Liu, JO | 1 |
| Olaleye, OA | 1 |
| Maimaiti, R | 1 |
| Pan, K | 1 |
| Mijiti, P | 1 |
| Wubili, M | 1 |
| Musa, M | 1 |
| Andersson, R | 1 |
| Scherrer, AU | 1 |
| Sirgel, F | 1 |
| Lesosky, M | 1 |
| Aung, NM | 1 |
| Hanson, J | 1 |
| Kyi, TT | 1 |
| Htet, ZW | 1 |
| Cooper, DA | 1 |
| Boyd, MA | 1 |
| Kyi, MM | 1 |
| Saw, HA | 1 |
| Fenner, L | 1 |
| Forster, M | 1 |
| Braitstein, P | 1 |
| Lewden, C | 1 |
| Schechter, M | 1 |
| Kumarasamy, N | 1 |
| Pascoe, M | 1 |
| Sprinz, E | 1 |
| Bangsberg, DR | 1 |
| Sow, PS | 1 |
| Dickinson, D | 1 |
| Fox, MP | 1 |
| McIntyre, J | 1 |
| Khongphatthanayothin, M | 1 |
| Dabis, F | 1 |
| Brinkhof, MW | 1 |
| Wood, R | 1 |
| Egger, M | 1 |
| Thee, S | 1 |
| Seddon, JA | 2 |
| Seifart, HI | 1 |
| Werely, CJ | 1 |
| Rosenkranz, B | 1 |
| Roll, S | 1 |
| Magdorf, K | 1 |
| Kabali, C | 1 |
| von Reyn, CF | 2 |
| Brooks, DR | 1 |
| Waddell, R | 1 |
| Mtei, L | 1 |
| Bakari, M | 2 |
| Matee, M | 1 |
| Pallangyo, K | 1 |
| Arbeit, RD | 2 |
| Lahey, T | 1 |
| Egwaga, S | 1 |
| Evans, D | 1 |
| Takuva, S | 1 |
| Rassool, M | 1 |
| Firnhaber, C | 1 |
| Maskew, M | 1 |
| Abebe, G | 1 |
| Abdissa, K | 1 |
| Abdissa, A | 1 |
| Apers, L | 1 |
| Agonafir, M | 1 |
| de-Jong, BC | 1 |
| Colebunders, R | 1 |
| Marais, BJ | 1 |
| Jordaan, A | 1 |
| Victor, T | 1 |
| Castell, S | 1 |
| Guglielmetti, L | 1 |
| Lattuada, E | 1 |
| Lanzafame, M | 1 |
| Vento, S | 1 |
| Trindade, MÂ | 1 |
| Miyamoto, D | 1 |
| Benard, G | 1 |
| Sakai-Valente, NY | 1 |
| Vasconcelos, Dde M | 1 |
| Naafs, B | 1 |
| Shaweno, D | 1 |
| Worku, A | 1 |
| Cobelens, F | 1 |
| van Kampen, S | 1 |
| Ochodo, E | 1 |
| Atun, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults[NCT01782950] | Phase 4 | 400 participants (Anticipated) | Interventional | 2013-02-28 | Recruiting | ||
| A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TB[NCT05124678] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-12-07 | Recruiting | ||
| A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277] | Phase 2 | 130 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
| A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis[NCT00216385] | Phase 3 | 2,070 participants | Interventional | 2005-01-31 | Recruiting | ||
| Randomized Non-inferiority Trial Comparing the Nevirapine-based Antiretroviral Therapy Versus the Standard Efavirenz-based ART for the Treatment of HIV-TB Co-infected Patients on Rifampicin-based Therapy (ANRS 12146 CARINEMO)[NCT00495326] | Phase 2/Phase 3 | 570 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Long Term Study of 2 Isoniazid (INH) Prophylactic Regimens With Concomitant Cotrimoxazole (CTX) in HIV-infected Children - Impact on Morbidity, Mortality, Bacterial Resistance and Incidence of Tuberculosis[NCT00330304] | Phase 3 | 450 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Impact of Nursing Interventions on Adherence to Treatment With Anti-tuberculosis Drugs in Children and Adolescents[NCT03230409] | 359 participants (Actual) | Interventional | 2014-01-01 | Completed | |||
| Using Biomarkers to Predict TB Treatment Duration[NCT02821832] | Phase 2 | 946 participants (Actual) | Interventional | 2017-06-21 | Active, not recruiting | ||
| Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial[NCT00640887] | Phase 2 | 48 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| Does Providing Medical Personnel in the AMPATH Network With Patient-specific Reminders Regarding TB That Are Generated From a Patient's EMR Improve the Prevalence of IPT Initiation and Decrease the Time From Screening to Treatment?[NCT01934309] | 3,782 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299] | Phase 4 | 302 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
| Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers[NCT03892161] | Phase 1 | 17 participants (Actual) | Interventional | 2018-04-12 | Terminated (stopped due to Risks to participation) | ||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)[NCT01637558] | Phase 4 | 200 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Pilot Study to Evaluate Video Observed Treatment Among Tuberculosis Patients From Lambaréné Using an Instant Messenger Application[NCT05865626] | 30 participants (Actual) | Interventional | 2018-10-10 | Completed | |||
| A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177] | Phase 4 | 96 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Estimation of the lower bound of a one-sided 95% confidence interval of the difference in success rates between arms B and C. If the lower bound is greater than -7%, this will be evidence that the treatment-shortening arm is not inferior to the standard duration arm. (NCT02821832)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Cured | Confirmed relapses | Late withdrawal, lost to follow-up | Probable relapses | Treatment Failure | |
| Arm A | 217 | 5 | 13 | 1 | 1 |
| Arm B | 121 | 1 | 9 | 1 | 0 |
| Arm C | 117 | 9 | 6 | 3 | 4 |
Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | percent (Number) |
|---|---|
| INH and Vitamin B6 | 8.3 |
Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| INH and Vitamin B6 | 32 |
Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 80 |
Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 308 |
INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation
| Intervention | pmol/mg (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 36.0 | 37.8 |
Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 31.3 | 43.9 |
"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH
| Intervention | days (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 30 | 30 |
The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At 3 months72558043 | At 6 months72558043 | |||||||||||
| Excellent | Very good | Good | Fair | Poor | Very poor | |||||||
| INH and Vitamin B6 | 160 | |||||||||||
| INH and Vitamin B6 | 79 | |||||||||||
| INH and Vitamin B6 | 38 | |||||||||||
| INH and Vitamin B6 | 2 | |||||||||||
| INH and Vitamin B6 | 124 | |||||||||||
| INH and Vitamin B6 | 90 | |||||||||||
| INH and Vitamin B6 | 41 | |||||||||||
| INH and Vitamin B6 | 4 | |||||||||||
| INH and Vitamin B6 | 0 | |||||||||||
| INH and Vitamin B6 | 1 | |||||||||||
13 reviews available for isoniazid and Co-infection
| Article | Year |
|---|---|
Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis.
Topics: Adolescent; Adult; Aged; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; Coi | 2021 |
Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.
Topics: Adult; Anti-Retroviral Agents; Antibiotic Prophylaxis; Antitubercular Agents; CD4 Lymphocyte Count; | 2021 |
Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.
Topics: Africa; Anti-HIV Agents; Antitubercular Agents; Asia; Body Weight; Central Nervous System Diseases; | 2018 |
Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Child, Preschool; Coinfection; | 2013 |
Drug-resistant tuberculous meningitis.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Bacterial Proteins; Catalase; Child; Coinfection; DNA | 2013 |
Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data.
Topics: Acquired Immunodeficiency Syndrome; Antitubercular Agents; Coinfection; Developing Countries; HIV In | 2014 |
Tuberculosis and HIV co-infection in children.
Topics: Child; Coinfection; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Incidence; | 2014 |
Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Child; Coinfection; Community Health Services; Drug Administration Schedule; | 2015 |
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
Topics: Antirheumatic Agents; Antitubercular Agents; Coinfection; Comorbidity; Disease Management; Drug User | 2015 |
Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antituber | 2015 |
New vaccines for the prevention of tuberculosis in human immunodeficiency virus infection.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte | 2012 |
Leprosy and tuberculosis co-infection: clinical and immunological report of two cases and review of the literature.
Topics: Adult; Brazil; Coinfection; Female; Humans; Immunity, Cellular; Interferon-gamma; Interleukin-12; Is | 2013 |
Research on implementation of interventions in tuberculosis control in low- and middle-income countries: a systematic review.
Topics: Algorithms; Antitubercular Agents; Coinfection; Cost-Benefit Analysis; Delivery of Health Care; Deve | 2012 |
15 trials available for isoniazid and Co-infection
| Article | Year |
|---|---|
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.
Topics: Adult; Antitubercular Agents; Area Under Curve; Coinfection; Drug Administration Schedule; Drug Dosa | 2013 |
Impact of tuberculosis treatment on CD4 cell count, HIV RNA, and p24 antigen in patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Biomarkers; CD4 Lymphocyte Count; Coinfection; Dietary Supplements; Dr | 2013 |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; Half-Life; | 2014 |
Isoniazid preventive therapy in HIV-infected children on antiretroviral therapy: a pilot study.
Topics: Age Factors; Anti-HIV Agents; Antitubercular Agents; Child Mortality; Child, Preschool; Coinfection; | 2014 |
Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Topics: Age Factors; Antitubercular Agents; Biomarkers; Biotransformation; Child; Chromatography, High Press | 2014 |
Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Topics: Age Factors; Antitubercular Agents; Biomarkers; Biotransformation; Child; Chromatography, High Press | 2014 |
Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Topics: Age Factors; Antitubercular Agents; Biomarkers; Biotransformation; Child; Chromatography, High Press | 2014 |
Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Topics: Age Factors; Antitubercular Agents; Biomarkers; Biotransformation; Child; Chromatography, High Press | 2014 |
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, C | 2014 |
Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Black People; Coinfection; Cross-Over Studies; | 2014 |
Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.
Topics: Allied Health Personnel; Antitubercular Agents; Bacteriological Techniques; Brazil; Coinfection; Cos | 2014 |
Do clinical decision-support reminders for medical providers improve isoniazid preventative therapy prescription rates among HIV-positive adults? Study protocol for a randomized controlled trial.
Topics: Antitubercular Agents; Clinical Protocols; Coinfection; Decision Support Techniques; Drug Prescripti | 2015 |
Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Coinfection; Ethambutol; Femal | 2016 |
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
Topics: Anti-Bacterial Agents; Area Under Curve; Coinfection; Drug Dosage Calculations; Ethambutol; Female; | 2016 |
Source case identification in HIV-exposed infants and tuberculosis diagnosis in an isoniazid prevention study.
Topics: Age Factors; Antitubercular Agents; Coinfection; Early Diagnosis; Female; HIV Infections; Humans; In | 2016 |
Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
Topics: Antitubercular Agents; Area Under Curve; Child, Preschool; Coinfection; Female; HIV Infections; Huma | 2011 |
Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; CD4 Lymp | 2011 |
56 other studies available for isoniazid and Co-infection
| Article | Year |
|---|---|
Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.
Topics: Antitubercular Agents; Child; Child, Preschool; Coinfection; HIV Infections; Humans; Isoniazid; Pyra | 2023 |
Body mass index variation over time and associated factors among HIV-positive adults on second-line ART in north-west Ethiopia: a retrospective follow-up study.
Topics: Adult; Anti-HIV Agents; Anti-Infective Agents; Antiretroviral Therapy, Highly Active; Body Mass Inde | 2019 |
Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Biological Availability; CD4 L | 2020 |
Incidence and determinants of tuberculosis among HIV-positive individuals in Addis Ababa, Ethiopia: A retrospective cohort study.
Topics: Adolescent; Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Disease-Free Survival; Ethio | 2020 |
Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis.
Topics: Adult; Antitubercular Agents; Coinfection; Female; HIV Infections; Humans; Isoniazid; Male; Mass Scr | 2020 |
Drug-resistant TB prevalence study in 5 health institutions in Haiti.
Topics: Adult; Antitubercular Agents; Coinfection; Cross-Sectional Studies; Drug Resistance, Multiple, Bacte | 2021 |
Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Combinations; Ethambutol; HIV Infections | 2017 |
Distribution scheme of antituberculosis drug resistance among HIV patients in a referral centre over 10 years.
Topics: Adult; Antitubercular Agents; Coinfection; Cross-Sectional Studies; Drug Resistance, Multiple, Bacte | 2017 |
Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Biomedical Research; CD4 Lymphocyte Count; Coh | 2017 |
A retrospective study on tuberculosis treatment outcomes at Jinka General Hospital, southern Ethiopia.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Combinations; Ethambutol; Ethiopia; Fema | 2017 |
Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.
Topics: Adolescent; Age Factors; Antitubercular Agents; Body Weight; Child; Child, Preschool; Coinfection; D | 2018 |
Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a five-year retrospective analysis.
Topics: Adolescent; Adult; Aftercare; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Directly O | 2018 |
Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?
Topics: Antitubercular Agents; Coinfection; Drug Monitoring; HIV; HIV Infections; Humans; Isoniazid; Rifampi | 2018 |
Burden, spectrum and outcomes of children with tuberculosis diagnosed at a district-level hospital in South Africa.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Coinfection; Comorbidity; Cost of Illnes | 2018 |
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Topics: Adult; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Resistance, Multiple, Bacterial; E | 2019 |
Therapeutic Drug Monitoring: The Need for Practical Guidance.
Topics: Coinfection; Drug Monitoring; HIV; HIV Infections; Humans; Isoniazid; Rifampin; Sputum; Tuberculosis | 2019 |
Rapid drug susceptibility testing and treatment outcomes for multidrug-resistant tuberculosis in Peru.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Female; HIV Infections; Humans; Isoniazid; Lo | 2018 |
Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children.
Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 2019 |
Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethiona | 2019 |
Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
Topics: Adult; Antitubercular Agents; Chemoprevention; Coinfection; Female; HIV Infections; HIV-1; Humans; I | 2019 |
Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009-2016: survival model approach.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Coinfection; Ethiopia; Female; HIV; HIV Infec | 2019 |
Incidence and predictors of tuberculosis among HIV-positive children at Adama Referral Hospital and Medical College, Oromia, Ethiopia: a retrospective follow-up study.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; Coinfection; Ethiopia; Femal | 2019 |
Latent tuberculosis infection: screening and treatment in an urban setting.
Topics: Adult; Antitubercular Agents; Coinfection; Connecticut; Directly Observed Therapy; Emigrants and Imm | 2013 |
Undetected multidrug-resistant tuberculosis amplified by first-line therapy in mixed infection.
Topics: Aged; Antitubercular Agents; Coinfection; Culture Techniques; Delayed Diagnosis; Drug Resistance, Mu | 2013 |
Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Checklist; Coinfection; Ethiopia; Female; | 2013 |
Detection of drug resistant Mycobacterium tuberculosis among patients with and without HIV infection in a rural setting.
Topics: Antitubercular Agents; Case-Control Studies; Coinfection; Drug Resistance, Bacterial; Drug Resistanc | 2013 |
Isoniazid preventive therapy use among patients on antiretroviral therapy: a missed opportunity.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; CD4 Lymphocyte Count; Chi-Square Distribution; Coinfe | 2014 |
Determinants of tuberculosis treatment completion among newborns in a high-burden setting.
Topics: Adult; Age Factors; Antitubercular Agents; Caregivers; Chi-Square Distribution; Coinfection; Female; | 2014 |
Investigating gender disparities in the profile and treatment outcomes of tuberculosis in Ebonyi state, Nigeria.
Topics: Adult; Antitubercular Agents; Cohort Studies; Coinfection; Ethambutol; Female; Health Status Dispari | 2015 |
Severe meningoencephalitis co-infection due to Cryptococcus neoformans and Mycobacterium tuberculosis in a child with systemic lupus erythematosus.
Topics: Amphotericin B; Antitubercular Agents; Child; Coinfection; Cryptococcosis; Cryptococcus neoformans; | 2015 |
Isoniazid preventive therapy in medium-incidence settings: the price is right.
Topics: Antitubercular Agents; Coinfection; Drug Costs; HIV Infections; Humans; Isoniazid; Latent Tuberculos | 2014 |
Effective anti-tuberculosis therapy correlates with plasma small RNA.
Topics: Adult; Antitubercular Agents; Biomarkers; Coinfection; Ethambutol; Female; Gene Expression Profiling | 2015 |
High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study.
Topics: Adult; Antitubercular Agents; Coinfection; Ethambutol; Female; Follow-Up Studies; HIV Infections; Hu | 2015 |
Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a "Low-Level" rpoB Mutation L511P - Insights into a Mechanism of Resistance Escalation.
Topics: Adolescent; Adult; Antitubercular Agents; Bacterial Proteins; Coinfection; Disease Outbreaks; DNA-Di | 2015 |
Isoniazid exposure and pyridoxine levels in human immunodeficiency virus associated distal sensory neuropathy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Arylamine N-Acetyltransferase; Coinfection; Female; HI | 2015 |
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Biotransfo | 2016 |
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Biotransfo | 2016 |
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Biotransfo | 2016 |
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Biotransfo | 2016 |
Prevalence of drug resistant TB among outpatients at an HIV/TB clinic in Lilongwe, Malawi.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Coinfection; Female; HIV Infections; Humans; | 2015 |
Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case-control study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Case-Control Studies; CD4 Lymph | 2016 |
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Topics: Adolescent; Age Factors; Antitubercular Agents; Child; Child, Preschool; Chromatography, Liquid; Coi | 2016 |
Isoniazid therapy for Mycobacterium tuberculosis infection in HIV clinics, Los Angeles, California.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Coinfection; Cross-Sectional Studies; Fema | 2016 |
Tuberculosis Treatment Outcome and Drug Resistance in Lambaréné, Gabon: A Prospective Cohort Study.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Coinfection; Drug Resistance, Mul | 2016 |
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Area Under Cur | 2016 |
Surveillance provides insight into epidemiology and spectrum of culture-confirmed mycobacterial disease in children.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; Coinfection; Epidemiological | 2016 |
Health system challenges: An obstacle to the success of isoniazid preventive therapy.
Topics: Antitubercular Agents; Coinfection; Delivery of Health Care; Disease Management; Female; HIV Infecti | 2016 |
Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis.
Topics: Aminopeptidases; Anti-HIV Agents; Antitubercular Agents; Bacterial Proteins; Coinfection; Dose-Respo | 2016 |
High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China.
Topics: Adult; Chemoprevention; China; Coinfection; Cross-Sectional Studies; Female; HIV Infections; HIV-1; | 2017 |
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; HIV Infec | 2017 |
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; HIV Infec | 2017 |
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; HIV Infec | 2017 |
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; HIV Infec | 2017 |
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; HIV | 2017 |
HIV care in Yangon, Myanmar; successes, challenges and implications for policy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Posit | 2017 |
Tuberculosis in HIV programmes in lower-income countries: practices and risk factors.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Co | 2011 |
Prevalence of peripheral neuropathy in antiretroviral therapy naïve HIV-positive patients and the impact on treatment outcomes--a retrospective study from a large urban cohort in Johannesburg, South Africa.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Female; HIV Infections; HIV-1; Humans; I | 2012 |
Relatively low primary drug resistant tuberculosis in southwestern Ethiopia.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Cross-Sectional Studies; Drug Resistance, Mul | 2012 |
The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Child, Preschool; C | 2012 |
Completion of isoniazid preventive therapy and survival in HIV-infected TST-positive adults in Tanzania.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Coinfection; Female; HIV Infections; H | 2012 |
Isoniazid preventive therapy in human immunodeficiency virus infection.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Coinfection; Female; HIV Infections; H | 2012 |
Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Drug Administration Schedule; Fem | 2012 |